In this phase 2b trial , we randomly assigned 160 patients with newly diagnosed , smear-positive , multidrug-resistant tuberculosis to receive either 400 mg of bedaquiline once daily for 2 weeks , followed by 200 mg three times a week for 22 weeks , or placebo , both in combination with a preferred background regimen .